Who Generates More Revenue? Ionis Pharmaceuticals, Inc. or ACADIA Pharmaceuticals Inc.

Ionis vs. ACADIA: A Decade of Revenue Rivalry

__timestampACADIA Pharmaceuticals Inc.Ionis Pharmaceuticals, Inc.
Wednesday, January 1, 2014120000214161000
Thursday, January 1, 201561000283703000
Friday, January 1, 201617331000346620000
Sunday, January 1, 2017124901000507666000
Monday, January 1, 2018223807000599674000
Tuesday, January 1, 20193390760001123000000
Wednesday, January 1, 2020441755000729000000
Friday, January 1, 2021484145000810000000
Saturday, January 1, 2022517235000587000000
Sunday, January 1, 2023726437000787647000
Loading chart...

Data in motion

Revenue Race: Ionis vs. ACADIA

In the competitive landscape of biotechnology, revenue generation is a key indicator of success. Over the past decade, Ionis Pharmaceuticals, Inc. and ACADIA Pharmaceuticals Inc. have been vying for dominance. From 2014 to 2023, Ionis consistently outperformed ACADIA, with Ionis peaking in 2019 at nearly double ACADIA's revenue. However, ACADIA has shown remarkable growth, increasing its revenue by over 600% from 2014 to 2023. In 2023, Ionis maintained a slight edge, generating approximately 8% more revenue than ACADIA. This trend highlights Ionis's steady leadership, but ACADIA's rapid growth trajectory suggests a potential shift in the coming years. As both companies continue to innovate, investors and industry watchers should keep a close eye on their financial performances, as they reflect broader trends in the biotech sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025